Inclusion Criteria:

1. Patients with histologically-proven, by biopsy or cytology, unresected lung cancer of
the following histological types: squamous cell carcinoma; adenocarcinoma;
undifferentiated large cell carcinoma, and non-small cell, not otherwise specified
(NOS, diagnosis on cytology alone)

2. Patients with American Joint Committee on Cancer (AJCC) Stage I, II, IIIA, or IIIB
with detectable tumour that can be encompassed by radiation therapy fields, including
both primary tumour and the involved regional lymph nodes.

3. Patients must be deemed to be suitable to undergo definitive (i.e. potentially
curable) chemoradiotherapy or radiotherapy by the treating Physician.

4. The prescribed radiotherapy dose must be a minimum of 60 Gy in 30 fractions

5. Male or female ≥ 18 years of age. If female of child bearing potential and outside
the window of 10 days since the first day of the last menstrual period, a negative
pregnancy test is required.

6. ECOG/Zubrod status 0-1

7. Patients must have at least one measurable lesion ≥ 1 cm on CT

8. Able and willing to follow instructions and comply with the protocol

9. Provide written informed consent prior to participation in the study

Exclusion Criteria:

1. Patients who have undergone complete or subtotal tumour resection

2. Patients with post-resection intrathoracic tumour recurrence

3. Patients eligible for definitive surgery (patients who are eligible for surgery, but
surgery did not proceed are eligible for this trial)

4. No distant or metastasis, prior chemotherapy, or thoracic neck or radiotherapy

5. Evidence of any small cell histology

6. Prior or concurrent malignancy (except non-melanomatous skin cancer) unless
disease-free for at least 5 years

7. Inability to lay in supine position for approximately one hour

8. Nursing or pregnant females

9. Aged less than 18 years